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Infection with the SARS-associated coronavirus (SARS-CoV) induces an atypical pulmonary disease with a high lethality rate. Although the
initial SARS epidemic was contained, sporadic outbreaks of the disease still occur, suggesting a continuous need for a vaccine against this virus.
We therefore explored exosome-based vaccines containing the spike S proteins of SARS-CoV. S-containing exosomes were obtained by replacing
the transmembrane and cytoplasmic domains of the S protein by those of VSV-G. The immunogenicity and efficacy of the S-containing exosomes
were tested in mice and compared to an adenoviral vector vaccine expressing the S protein. Both, S-containing exosomes and the adenoviral
vector vaccine induced neutralizing antibody titers. After priming with the SARS-S exosomal vaccine and boosting with the adenoviral vector the
neutralizing antibody titers exceeded those observed in the convalescent serum of a SARS patient. Both approaches were effective in a SARS-S-
expressing tumor challenge model and thus warrant further investigation.
© 2007 Elsevier Inc. All rights reserved.Keywords: SARS-CoV; S spike; Vaccine; Exosome; Adenoviral vectorIntroduction
First reported in 2002, the severe acute respiratory syndrome
(SARS) is caused by the newly emerged human coronavirus
(SARS-CoV) (Drosten et al., 2003a, 2003b). The disease is
characterized by an atypical severe pulmonary disease with high
lethality rate (Chan-Yeung, 2004; Chan-Yeung and Yu, 2003;
Chan-Yeung et al., 2003; Ho et al., 2003). Within few months
after the first outbreak reported in the Guangdong province of
China, the SARS-CoV rapidly spread out via international
travelers and became a serious problem of public health
worldwide. To date several isolated SARS-CoV infections are
still occurring mainly in Asia (Peiris et al., 2004) although the
major outbreak has been contained since 2003. This indicates
that the SARS-CoV infection still represents a threat for the
public health. In the absence of an effective therapy against
SARS, the development of an effective vaccine is still needed.⁎ Corresponding author. Fax: +49 234 3214352.
E-mail addresses: Seraphin.Kuate@rub.de, sekuate@yahoo.com (S. Kuate).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.12.011The SARS-CoV is an enveloped, positive-stranded RNAvirus
with a genome of 29,727 nucleotides that encodes four structural
proteins including the spike glycoprotein (S), the nucleocapsid
protein (N), the membrane protein (M) and the small envelope
glycoprotein (E), and several nonstructural proteins most of
which, like in other coronaviruses, are of unknown functions
(Marra et al., 2003; Rota et al., 2003). The spike S protein binds to
members of the DC-SIGN family and to the angiotensin-
converting enzyme 2 (ACE2) (Jeffers et al., 2004; Li et al.,
2003; Wang et al., 2004), thereby mediating the entry of the virus
into the target cells. Therefore, this protein represents a good
target for vaccine development against SARS-CoV.
Exosomes released from dendritic cells or cancer cells have
been proposed as vaccine candidates for immunotherapy of
tumors (Andre et al., 2001, 2002; Chaput et al., 2003, 2005;
Delcayre et al., 2005; Taieb et al., 2005; Zitvogel et al., 1998).
They are small membrane vesicles with a diameter of 30 to
100 nm, which are released via multivesicular bodies from a
variety of different cell types (Schartz et al., 2002). The
proteomic profile of exosomes differs substantially from that of
cell lysates (Amigorena, 2000; Mears et al., 2004). A number of
Fig. 1. Construction and expression of the hybrid S protein. (A) Schematic
representation of wild-type and chimeric S proteins. The open boxes represent
amino acid sequences from the SARS-CoV-S protein, the black line represents
amino acid sequences from the VSV-G and the filled circle represents the VSV-
G tag sequence. The numbers above the sequences indicate the position of the
amino acids in the corresponding parental polypeptide. LP: leader peptide; TM:
transmembrane domain; CD: cytoplasmic domain. (B) Expression of wild-type
and chimeric S proteins in transiently transfected cells. The expression plasmids
for the indicated recombinant proteins were transiently transfected into 293T
cells and Western blot analysis of cell lysates were performed using an anti-S1
antiserum. Numbers on the left-hand side of the figure indicate the position of
molecular weight size markers. Swt: wild-type S protein; SGTM: hybrid S protein.
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MHC-I molecules are enriched in these vesicles (Denzer et al.,
2000; Peche et al., 2003; Admyre et al., 2003; Hemler, 2003;
Andre et al., 2004).
Exosomes can be taken-up by dendritic cells, leading to
presentation of MHC-I/peptide complexes from the exosomes
by the dendritic cells (Andre et al., 2004). Cellular components
of the exosomes such as heat shock proteins were reported to
enhance the immunogenicity and efficacy of exosome-based
cancer vaccines (Chen et al., 2006). We therefore analyzed,
whether the exosomal vaccine approach could also be exploited
for the development of vaccines against enveloped viruses, such
as the SARS coronavirus. To incorporate the S protein of the
SARS coronavirus (SARS-S) into exosomes the cytoplasmic
and transmembrane domains of SARS-S were replaced by those
of the G protein of vesicular stomatitis virus. This chimeric
protein (SGTM) was efficiently expressed on the cell surface,
allowed entry of pseudotyped retroviral vectors, and was
incorporated into exosomes. SGTM-containing exosomes were
tested for their immunogenicity in mouse models as a novel
protein vaccine against the SARS-CoV. Given the immunosti-
mulatory properties of VSV-G (Marsac et al., 2002; Kuate et al.,
2006), we also explored the immunogenicity of exosomes
generated from cells coexpressing SARS-S and VSV-G.
Results
Construction and transient expression of wild-type and
chimeric S of SARS-CoV
The S protein of the SARS-CoV, a type I transmembrane
glycoprotein, is composed of an ectodomain (amino acids 17–
1195), a transmembrane domain (TM) (amino acids 1196–
1218), and a cytoplasmic domain (CD) (amino acids 1219 to
1255) (Giroglou et al., 2004; Spiga et al., 2003; Zeng et al.,
2004). To generate the expression plasmid for the chimeric S
protein, the coding region for the transmembrane and
cytoplasmic domains of the S protein were replaced by those
of VSV-G (GTM). A schematic representation of the encoded
recombinant polypeptides is shown in Fig. 1A.
In order to assess the expression of the recombinant proteins,
cell lysates from 293T cells transiently transfected with different
SARS-CoV-S expression plasmids were analyzed by Western
blot. For the detection of the S protein, a polyclonal antiserum
raised against amino acids 441–453 of the S1 subunit was used.
As shown in Fig. 1B the wild-type as well as the recombinant
proteins were expressed in transfected cells. The S precursor
polypeptide with a molecular weight of approximately 180 kDa
could be detected in samples transfected with pSwt or pSGTM.
The antiserum also reacted with a cellular protein with an
approximate molecular weight of 100 kDa (Fig. 1B).
Cell surface expression of the wild-type and chimeric
S proteins
The fusion of the ectodomain of the S protein to the N-
terminus of the TM of VSV-G should lead to expression of thehybrid protein in a membrane-bound form. The results of
immunofluorescence staining (Fig. 2A) of transfected 293T
cells with a SARS-convalescent serum indeed suggest such a
localization for Swt and SGTM. To further confirm cell surface
expression, 293T cells transfected with S expression plasmids
were stained with a SARS-convalescent serum without
disrupting the cellular membrane. As shown in Fig. 2B the
wild type as well as the hybrid S proteins were expressed on the
cell surface. The mean fluorescence intensity of cells expressing
SGTM was higher compared to that of cells expressing Swt (Fig.
2B). To further compare expression levels of SGTM and Swt on
the surface of the cell, surface proteins of transfected cells were
biotinylated, lysed and precipitated by avidin-coupled beads.
Western blot analysis of the precipitates revealed efficient
expression of SGTM but not Swt on the surface of the cell (Fig.
2C, right panel). Both proteins could be detected in total cell
lysates (Fig. 2C, left panel). These results indicate that the
transmembrane and cytoplasmic domains of VSV-G mediate
more efficient transport of the S protein ectodomain to the cell
membrane than the homologous domains.
Functional assay for the chimeric S protein
The production of a fully functional hybrid S protein
retaining much of the conformation of the parental S protein is
important for vaccine design, since neutralizing antibodies
generated after immunization with the hybrid S protein should
also be able to neutralize the wild-type SARS-CoV. In addition,
it could be beneficial if receptor induced conformational
changes of the hybrid S protein also mimic those of the parental
S protein. To test whether the SGTM protein is functionally
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with either the wild-type or the hybrid S protein. Vector titers
were determined on ACE2-transfected 293T cells, which were
more susceptible for vector transduction than VeroE6 cells (data
not shown). Infectious SIV, HIV and MLV vectors were
obtained using the hybrid S protein (SGTM). Titers in the
absence of a viral surface protein were below 5 GFU/ml.
Incorporation of SGTM into vector particles (Fig. 3A) seemed to
correlate with the titers obtained for SIV, HIV-1, or MLV
vectors (Fig. 3B), while similar titers were obtained for all threevectors after pseudotyping with VSV-G. Vector titers of SGTM
pseudotypes were only 1.5- to 2.7-fold higher than those
obtained by pseudotyping with Swt, although the latter could
hardly be detected in the particle preparations.
Incorporation of S proteins into exosomes
The high efficiency of expression of SGTM on the surface of
cells may also lead to increased incorporation into exosomes
released from transfected cells. In order to assess this, Western
blot analyses were performed on pelleted vesicles from pSwt-
and pSGTM-transfected cells using anti-S1 antibodies. As shown
in Fig. 4A, the S protein could not be detected in the sample
from pSwt-transfected cells. In contrast, the SGTM protein could
be detected in the pelleted supernatant of pSGTM-transfected
cells. We also checked for the presence of proteins characteristic
for exosomes including a heat shock protein (HSP90) and the
tetraspanin protein CD82. Western blot analysis of vesicles
derived from cells transfected with pSGTM revealed the presence
of both proteins with a molecular weight of 90 kDa and 45 kDa
respectively (Fig. 4A). In addition to these expected proteins,
the Western blot analysis with the anti-CD82 antibody revealed
incorporation of an unknown protein with a molecular weight of
about 85 kDa. In contrast, HSP90, CD82, and the CD82 related
protein were not detectable in blots of samples from pSwt- or
mock-transfected cells (Fig. 4A). The presence of HSP90 and
CD82 proteins correlated with incorporation of the SGTM into
pelletable vesicles, indicating that SGTM, but not the wild-type S
protein (Swt) may enhance release of exosomes into the
conditioned media.
In order to check if SGTM was membrane bound, SGTM was
pelleted from the supernatant of transfected cells through a 20%
sucrose cushion, resuspended, and incubated with n-octyl-β-D-
glucopyranoside (OG), a mild detergent solubilizing lipid
membranes. The OG-treated sample was layered on a 20%
sucrose cushion followed by ultracentrifugation and Western
blot analysis of the pellet and the concentrated supernatant (Fig.
4B). After OG treatment, SGTM was almost exclusively found in
the supernatant. The absence of SGTM in the pellet was not due
to loss of SGTM during the whole procedure, since SGTM couldFig. 2. Cell surface expression of Swt and SGTM. (A) Immunofluorescence assay.
Cells transfected transiently with the indicated expression plasmids were
incubated with a convalescent serum of a SARS patient and bound antibodies
were detected using an FITC-conjugated anti-human secondary antibody. The
upper panel represents the 10-fold magnification of the image and the lower
panel a 40-fold magnification. (B) FACS analysis. 293T cells were transiently
transfected with plasmid encoding the wild-type S protein (Swt) or the hybrid
protein (SGTM) and FACS analysis was performed on intact cells using SARS
patient serum and FITC-conjugated anti human IgG. The level of protein
expression was expressed as mean fluorescence intensity (MFI). As negative
control, mock-transfected cells were used. (C) Biotinylation assay. 293T cells
were transfected with the expression plasmid for the indicated S proteins. Half of
the transfected cells were lysed directly, while the extracellular domains of the
membrane proteins of the other half were first biotinylated and then precipitated
by avidin beads. Both, lysates from transfected cells (cell lysate) and the
biotinylated and precipitated surface proteins (cell surface) were analyzed by
Western blot with the S1 antiserum. Numbers on the left-hand side of the figures
indicate the position of molecular weight size markers.
Fig. 3. Infectivity of retroviral vector particles pseudotyped with the SARS-S or
the SGTM protein. (A) SIV, HIVand MLV-based vectors pseudotyped with either
the S protein (Swt) or the hybrid SGTM were obtained by transient transfection of
293T cells. Cell lysates from transient transfections (upper panel) as well as
purified vector particles (SN) were subjected to Western blot analysis with the
anti-S1 antiserum. Numbers on the left-hand side of the figures indicate the
position of molecular weight size markers. (B) For the determination of the
vector titers the conditioned media from transfected cells were used to infect
293T cells transiently expressing the ACE2 receptor. Two days later, the GFP-
positive cells were counted and the titers were calculated as green fluorescence
forming unit (GFP)/ml.
29S. Kuate et al. / Virology 362 (2007) 26–37be repelleted in the absence of OG (Fig. 4B). Thus, SGTM seems
to be incorporated into membrane vesicles released from
transfected cells and resembling exosomal structures.
Immunogenicity of SARS-S-containing exosomes
To test the immunogenicity of the SARS-S-containing
exosomes, 293T cells were transiently transfected with the
SGTM expression plasmid. The serum-free conditioned media
were harvested and the exosomes were partially purified by
ultracentrifugation through a 20% sucrose cushion. Since we
previously observed that incorporation of VSV-G into immuno-
deficiency virus-like particles enhanced immune responses to
HIV-1 Gag (Kuate et al., 2006), we also coexpressed VSV-G and
SGTM in 293T cells and purified the released exosomes by
ultracentrifugation. Both exosome preparations contained similar
amounts of SGTM (Fig. 4C, left panel). The preparation ofexosomes from cells coexpressing VSV-G and SARS-S (G+
SGTM) contained both proteins (Fig 4C, right panel). In this
Western blot analysis, both proteins were detected using an
antibody recognizing the cytoplasmic domain of VSV-G. The
ratio of the band intensities of the SGTM and VSV-G proteins
therefore indicates that in the vaccine preparation VSV-G is
present at molar excess (Fig. 4C, right panel). These exosome-
based vaccines were compared to an adenoviral vector expressing
SGTM, since adenoviral vector vaccines were shown to induce
strong immune responses to a broad spectrumof antigens encoded
by the adenoviral vector. The adenoviral SGTM vector was
constructed using a modified pAd-Easy system (He et al., 1998;
Kuate et al., 2004). The adenoviral vector was purified by CsCl
gradient centrifugation and expression of SGTM was confirmed by
Western blot analysis (data not shown). We also explored a
prime–boost regimen of priming with the exosomal vaccine and
boosting with the adenoviral vector vaccine.
A single injection of the adenoviral vector expressing SGTM
induced antibodies binding to SARS-S expressed in murine B16
cells (Fig. 5A). For the exosomal vaccines two injections were
required to induce similar antibody levels to SARS-S (Fig. 5B).
Coexpression of VSV-G and SARS-S (G+SGTM) only led to a
slight increase in antibody levels to SARS-S, while the highest
antibody levels were obtained after priming with SGTM
exosomes and boosting with the adenoviral vector vaccine
(Fig. 5, right panel). Although the binding antibody levels were
significantly higher in all vaccinated groups compared to the
non-vaccinated control group (p<0.001, one-way ANOVA on
log-transformed MFI), the differences between the vaccinated
groups did not reach statistical significance.
For the determination of the neutralizing antibody titers, S-
pseudotyped retroviral vector-based (Figs. 6A, B) and wild-
type SARS-CoV-based (Fig. 6C) neutralization assays were
performed. When using S-pseudotypes for the neutralization
assay, the highest serum dilution reducing vector infectivity by
more than 90% was determined, in order to avoid minor
unspecific inhibitory effects of sera at high concentrations. The
highest neutralizing antibody titers were obtained in animals
that were primed with SGTM and boosted with Ad-SGTM
vectors (Fig. 6A). Comparison of neutralizing antibody titers of
this group to the group immunized once with Ad-SGTM
indicates that SGTM immunization had a priming effect (Fig.
6A). Two injections of the exosomal SGTM vaccine also
induced substantial neutralizing antibody titers that were
slightly higher if VSV-G was included in the exosomal vaccine
(Fig. 6A). The neutralizing antibodies specifically inhibited
SARS-S-mediated entry, since the same sera did not reduce the
titer of retroviral vectors containing the amphotropic MLV-Env
instead of SARS-S (Fig. 6A).
To compare the neutralizing activity of the antibodies
obtained from immunized mice to that obtained during natural
SARS coronavirus infection in humans, a convalescent serum
of a SARS patient obtained 10 weeks after onset of symptoms
was analyzed side by side with selected mouse sera using the
pseudotyped retroviral vector. Sera from SGTM+Ad-SGTM-
immunized mice inhibited vector infectivity more efficiently
than the convalescent serum of the SARS patient (Fig. 6B).
Fig. 4. Characterization of the S exosomal vaccines. (A) Incorporation of wild-type and chimeric S protein in exosomes. 293T cells were transfected with plasmids
expressing the indicated proteins and vesicles pelleted from the conditioned media were analyzed by Western blot for the presence of the S (upper band), HSP90 (middle
band) or CD82 (lower band) proteins using the indicated antibodies. (B) Membrane association of SGTM. Pelleted SGTM was resuspended, treated (+OG) with n-octyl-β-D-
glucopyranoside, and repelleted through a sucrose cushion by ultracentrifugation. After centrifugation, the pellet was harvested and supernatant (sup) was concentrated by
ultrafiltration. The samples obtained (pellet and sup) were analyzed for the presence of the S protein byWestern blot using the S1 antiserum. As controls, untreated (−OG)
pelleted SGTM, and pellets from the conditioned media of mock-transfected cells (Neg) were processed the same way. (C) Western blot analysis of the exosomal vaccines.
Conditioned media from 293T cells transfected with plasmid expressing the hybrid protein together (G+SGTM) or not (SGTM) with that expressing the VSV-G were
concentrated by ultracentrifugation and the exosomes were analyzed by Western blot using the S1 antiserum (left panel) or an anti-VSV-G antibody (right panel).
Fig. 5. Binding antibody levels. B16 cells stably expressing the S protein were
incubated with sera obtained after a single immunization (A) or the indicated
prime–boost regimen (B). After washing to remove unbound antibodies, cells
were incubated with FITC-labeled anti-mouse antibodies and FACS analysis
was performed to determine the mean fluorescence intensity of the samples.
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pseudotyped retroviral vectors, also neutralize wild-type SARS-
CoV, pooled antisera from the group of mice receiving two SGTM
injections or an SGTM prime and adenoviral vector boost im-
munization were tested in a virus neutralization assay.
Consistently, the highest neutralizing activity was obtained for
the SGTM prime adenoviral vector boost regimen, which induced
higher titers of neutralizing antibodies than those detected in the
convalescent serum of the SARS patient (Fig. 6C).
Efficacy of SARS-S-containing exosomes in a tumor challenge
model
A tumor challenge model was established to explore the
relative efficacy of different SARS-S-based vaccines. To this
end B16 melanoma cells were established stably expressing the
wild-type SARS-S protein. Non-immunized mice inoculated
with these cells develop tumors within 1 or 2 weeks after
injection (Fig. 7A, 7B). Immunized mice were challenged with
the tumor cells 2 weeks after a single immunization or 1 week
after the booster immunization. For single immunizations, the
rate of tumor growth was slightly delayed in vaccinated animals
compared to the controls (Fig. 7A). This delay was more
pronounced in Ad-SGTM-immunized animals. To compare the
rate of tumor growth in the different vaccine groups, one-way
ANOVA test was performed on log-transformed tumor volume
at day 15 after challenge. At this time point the tumor volume in
some of the control animals already reached 3500 mm3 (Fig.
7A). Larger tumor volumes were observed in control animals
compared with that obtained in the vaccine groups. However, a
statistically significant difference in tumor growth was found
only between control group and Ad-SGTM-immunized animals
(p<0.05).
For prime–boost immunization regimen, the same pattern of
tumor growth in the control mice as in single immunization
regimen was observed. In all vaccinees, the rate of tumor
Fig. 6. Neutralization assay. (A) Sera from mice immunized with the indicated
vaccines were diluted serially into serum-free DMEMmedium and incubated with
S-pseudotyped MLV vectors. The cocktail was added in triplicates to 293T cells
transiently expressing the ACE2 receptor. Two days later, GFP-positive cells were
counted under fluorescence microscope and the highest dilution that led to >90%
inhibition of the vector infectivity compared to control infection was taken as the
neutralizing antibody titer (closed symbols). The log2 of the titers is given. Control
infections for the specificity of the neutralizing antibodies were performed using
MLV-based vectors containing the amphotropic MLV Env (open symbols). (B)
Comparison of the neutralization activity of antisera from immunizedmice and that
of a convalescent SARS patient. The inhibition of S-pseudotyped MLV vectors
incubated with different dilutions of a control serum (C-Serum), a serum from a
SARS-recovered patient (P-Serum), or sera of mice immunized as indicated was
determined. The log2 of the serum dilution is given on the x-axis. (C) Virus
neutralization assay. Vero cells were infected in triplicates with the wild-type
SARS-CoV, incubated with different dilutions of antisera from the indicated
experimental animal groups, and monitored 3 to 5 days latter for formation of
cytopathic effects. The neutralizing antibody titer is presented as the highest
dilution of the antisera that prevent cytopathic effects in 66% of the wells.
Fig. 7. Determination of the tumor growth after challenge. (A) Single
immunization. Mice were challenged 2 weeks after a single immunization
with the indicated vaccines with B16 cells stably expressing the S protein. The
tumor growth was monitored daily and the volume was determined at a 3-day
interval. (B) Prime–boost immunization. Mice immunized as indicated were
challenged with the tumor cells 1 week after the second immunization and the
tumor growth was monitored.
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(Fig. 7B). As for single immunization, animals that received
Ad-SGTM as booster immunization (group SGTM+Ad-SGTM)
controlled efficiently the tumor growth. Control of tumor
growth was SARS-S specific as mice immunized twice with
SGTM did not control growth of B16 cells not expressing the S
protein (data not shown). A comparison of the tumor volume
at day 15 post challenge showed no statistically significant
difference between vaccine groups (Fig. 7B). However,
statistically significant differences were found when compared
the volume of the tumor in control animals to those
immunized with SGTM (p<0.01), G+SGTM (p<0.001) and
SGTM+Ad-SGTM (p<0.01).
Discussion
Exchanging the transmembrane domain and cytoplasmic
domain of SARS-CoV-S by the corresponding domains of
VSV-G altered the cellular fate of the S protein substantially.
The cytoplasmic domain of VSV-G has previously been shown
to determine the transport pathway (Hart et al., 1994; Andersson
et al., 1997) and the basolateral localization of VSV-G in
polarized cells (McQueen et al., 1986; Brown et al., 1989;
Compton et al., 1989). Fusing heterologous proteins to
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geted the heterologous protein to the cell surface and allowed
efficient incorporation into viral vector particles (Owens and
Rose, 1993; Jin and Wright, 2003). This was now also observed
for the ectodomain of SARS-CoV-S. The SGTM fusion protein
was expressed at higher levels at the cell surface compared to
the wild-type protein. In comparison to SGTM, incorporation of
wild-type S into viral particles was severely reduced. SGTM was
not only incorporated into viral particles but was also
functionally active as it allowed transduction of ACE2-
expressing cells with pseudotyped retroviral and lentiviral
vectors. This indicates that SARS-S-mediated fusion of the viral
membrane with the cellular membrane is not disturbed by the
heterologous transmembrane and cytoplasmic domains and
suggests that neutralizing epitopes of SARS-S are maintained in
SGTM.
Transfection of 293T cells with the expression plasmid for
SGTM also led to secretion of SGTM. Consistent with an
exosomal localization, secreted SGTM seemed to be membrane
bound and could be pelleted through a 20% sucrose cushion.
Western blot analysis of SGTM, but not Swt vesicles or vesicles
from mock-transfected cells, revealed the presence of HSP90
and CD82, two of several proteins that are characteristic for
exosomes (Wubbolts et al., 2003; Clayton et al., 2005).
Although exosomes are constitutively secreted from several
cell types as a consequence of fusion of multivesicular bodies
with the plasma membrane (Schartz et al., 2002), the lack of
detection of these proteins in Swt or mock-derived vesicles
suggests that SGTM either induces exosome formation or
enhances incorporation of HSP90 and CD82 into the exosomes.
It remains to be determined whether this function can be
mapped to the transmembrane or more likely to the cytoplasmic
domain of VSV-G.
In contrast to soluble protein vaccines, exosomes contain-
ing membrane-anchored ectodomains of viral surface proteins
should have multiple copies of the same viral protein exposed
on the surface of the same exosome thereby facilitating cross-
linking of the B cell receptor. In this respect, they mirror
virosomal vaccines that are made by reconstitution of purified
viral membrane proteins into liposomes. They differ from
virosomal vaccines by the fact that exosomes do not only
contain the viral protein, but also a wide array of cellular
proteins, some of which have been shown to support induction
of immune responses. Although exosomal vaccines have been
primarily raised interest due to the fact that they allow cross
presentation leading to the induction of CD8+ T cell
responses, the multimeric presentation of viral surface proteins
in their natural confirmation might also efficiently trigger viral
surface protein-specific B cell receptors, particularly if cellular
components of the exosome provide additional stimulatory
signals. Since this could also favor the induction of
neutralizing antibodies, we explored the potential of SGTM-
containing exosomes as a novel vaccine approach against
SARS coronavirus infections. Two injections of SGTM-
containing xenogenic exosomes without adjuvants were
sufficient to induce neutralizing antibody titers. After priming
with the SARS-S exosomal vaccine and boosting with anadenoviral vector the neutralizing antibody titers exceeded
those of a SARS-convalescent patient serum (Fig. 5C). In
previous immunization studies using soluble S proteins,
several immunizations in the presence of adjuvant were
necessary to generate reasonable neutralizing antibody titers
(Keng et al., 2005).
We previously observed that incorporation of fusion-
competent, but not fusion-deficient VSV-G into HIV-1-based
VLPs led to an approximate 100-fold increase of antibody
titers against the HIV-1 capsid protein (Kuate et al., 2006).
This indicates that the fusion activity of VSV-G is required
for its immunostimulatory properties and suggests that VSV-
G-mediated shuttling of VLP-associated antigens into parti-
cular cellular compartments can dramatically enhance
humoral immune responses. However, incorporation of
VSV-G into SGTM-containing exosomes did not lead to a
significant increase in binding or neutralizing antibodies
against SARS-S. Since SGTM itself is fusion-competent, the
enhancing effect of fusion-competent VSV-G might be
masked. Alternatively, the immunostimulatory properties of
VSV-G might differ depending on the type of co-administered
antigen. After fusion of the exosomal membrane with the
endosomal membrane, the large ectodomain of the membrane
anchored SGTM should be in the lumen of the endosome,
while HIV-1 capsid proteins localized within the VLP should
reach the cytoplasm. Although VSV-G and SGTM contain the
same cytoplasmic domain directing intracellular trafficking we
cannot formally exclude the possibility that VSV-G and SGTM
are localized on different exosomes, which might also explain
the poor enhancing effect of VSV-G on SARS-S antibody
titers.
Since the SGTM-containing exosomes were prepared from
human cells, they are expected to contain a number of human
proteins, which might be targeted by the murine immune
response. We therefore also determined the immunogenicity of
an adenoviral vector expressing SGTM. Injection of this
adenoviral vector into mice should lead to expression of
SGTM in the vaccinees and subsequent release of exosomes
containing SGTM, but no other heterologous proteins. A single
injection of the SGTM-expressing adenoviral vector induced
neutralizing antibodies and reduced the growth of SARS-S-
expressing tumor cells confirming the immunogenicity of
adenoviral vector vaccines. Whether the release of SGTM-
containing exosomes in vivo contributes to the strong immune
responses observed remains to be determined. Immune
responses to the adenoviral vector particle limit repeated
application of adenoviral vector vaccines (Bangari and Mittal,
2006; Barouch et al., 2004; Yang et al., 2003). We therefore
used a prime–boost regimen consisting of SGTM-containing
exosomes followed by the adenoviral vector boost. This prime–
boost regimen induced the highest neutralizing antibody titers,
which exceeded the titers obtained after a single adenoviral
vector immunization or two doses of SGTM-containing
exosomes.
The neutralizing antibody titers induced by immunization
paralleled the efficiency of control of growth of SARS-S-
expressing tumor cells. All mice receiving the heterologous or
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growth. A single injection of the SGTM-expressing adenoviral
vector inhibited tumor growth to a similar extent as the prime–
boost regimens. However, only transient suppression of the
tumor growth was observed. This growth pattern was
previously described for ovalbumin-immunized mice chal-
lenged with B16 cells stably expressing ovalbumin (MO4)
(Bonifaz et al., 2004). Selection of tumor cells not expressing
SARS-S and their subsequent outgrowth might explain this
observation.
We have chosen this tumor challenge model to avoid work
with infectious SARS coronavirus. Although we do not know at
present, whether this model predicts vaccine efficacy against
SARS coronavirus infections in animal models or in humans, it
represents an additional parameter allowing preclinical ranking
of different vaccine approaches to be further evaluated. Since
SGTM-containing exosomes and SGTM-expressing adenoviral
vectors induce neutralizing antibody titers that exceed those
observed in the convalescent serum of a SARS patient if
combined in prime–boost regimen and since humoral immunity
alone could control coronavirus replication in a murine model
(Yang et al., 2004), both approaches warrant further
investigation.
Materials and methods
Cell culture
The human embryonic kidney cell derivative 293T
(DuBridge et al., 1987) were maintained in Dulbecco's
modified Eagle's medium (DMEM) (Invitrogen, Karlsruhe,
Germany) supplemented with 10% fetal calf serum (FCS), L-
glutamine, penicillin and streptomycin. Vero cells were
maintained in minimal essential medium (MEM) (Invitrogen,
Karlsruhe, Germany) supplemented with 10% FCS.
Plasmids
The plasmids pLEGFP-N1 and pEGFP-C1 were purchased
from Clontech, Heidelberg, Germany. The construction of the
plasmids VCGΔBH (Kuate et al., 2004) SgpΔ2 (Schnell et al.,
2000) Hgpsyn (Wagner et al., 2000), pHIT-G (Fouchier et al.,
1997), HIV-CL-CG (Miyoshi et al., 1998), pcTatRev (South-
gate et al., 1990), pCAGG-S (Hofmann et al., 2004) and
pCDNA-ACE/Z (Hofmann and Pohlmann, 2004) has been
described. For the construction of the expression plasmids for
the chimeric S proteins, the transmembrane and cytoplasmic
domains (Chapple and Jones, 2002) of a codon-optimized
version of the G protein of vesicular stomatitis virus were
amplified from the plasmid pCD-Gsyn (unpublished data) using
the primers 5′atttaaatgaatcactcattgaccttcaagaattgggaaaatatgag-
caatatattaaatggcctttcggcgacaccggcctgagcaagaaccccatc and 5′
acaagctgctagccagccatagagcccaccgcatccccagcat, flanked with
the restriction enzymes SwaI and NheI respectively. The PCR
product was digested with SwaI and NheI, and inserted in frame
into the SwaI-NheI digested pSwt (pCAGG-S (Hofmann et al.,
2004)) generating pSGTM.Western blot analysis for S protein expression
293T cells were plated into 25 cm2 flasks and transfected
1 day later with 10 μg of pSwt or pSGTM together with 1 μg of
GFP-expressing plasmid (pEGFP-C1) in order to monitor
transfection efficiency. Two days later, transfected cells were
resuspended into 200 μl of protein loading buffer and samples
were denatured at 95 °C for 10 min. Fifteen microliters of each
sample was thereafter separated using 10% SDS-PAGE and the
proteins were transferred onto a nitrocellulose membrane
(Schleicher and Schuell Bioscience, Dassel, Germany) using
standard techniques. Blots were subsequently incubated with a
1:1000 dilution of a rabbit antiserum raised against S1 (Biomol
GmBH, Hamburg, Germany), then with 1:2000 diluted goat
anti-rabbit antiserum conjugated with horseradish peroxidase
(Sigma, Taufkirchen, Germany). After washings, protein bands
were detected using a commercially available chemilumines-
cence's Western blot detection kit (Biozym Scientific GmBH,
Oldendorf, Germany) according to the manufacturer's
instructions.
Immunofluorescence assay
293T cells were plated into 25 cm2 flasks and transfected
1 day later with 5 μg of pSwt, pSGTM or carrier DNA. Two days
later, cells were detached from the flasks using 20 mM of EDTA
in PBS, washed two times with PBS and transferred onto slides
by centrifugation using a cytospin centrifuge (Shandon,
Biomedical polymer Inc., Gardner, USA). Cells were thereafter
fixed for 10 min in cold acetone, and then incubated for 1 h with
30 μl of 1:50 diluted serum obtained from a SARS patient 10
weeks after his hospitalization. After washing to eliminate
unbound antibodies, cells were incubated for 30 min at 37 °C
with 30 μl of FITC-conjugated anti-human IgG (DakoCytoma-
tion GmbH, Hamburg, Germany), diluted 1:20 into 0.1% of
Evan's blue solution. After another washing step the presence of
green cells was monitored under a fluorescence microscope and
pictures were taken.
Characterization of cell surface expression
Cells were plated and transfected as described above with
5 μg of the pSwt or pSGTM. Two days after transfection, cells
were detached from the flask as described for the immuno-
fluorescence assay and washed three times with the FACS
buffer (2% FCS in PBS). 106 cells/well were transferred into
96-well, v-bottom microtiter plates and incubated for 30 min at
4 °C with 100 μl of patient serum diluted 1:50 into FACS buffer.
After three washes with FACS buffer, cells were incubated for
20 min in the dark at 4 °C with 100 μl of FITC-conjugated anti-
human IgG diluted 1:100 in FACS buffer containing propidium
iodide. After washing, cells were analyzed using FACS Calibur
(Becton Dickinson, Heidelberg, Germany). For the biotinyla-
tion assay, 293T cells were transfected with 10 μg of the
plasmids expressing the wild-type S proteins or its mutant. Two
days later half of the cells were lysed in loading buffer and used
for SDS-PAGE, while the other half was used for biotinylation
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Functional analysis of the hybrid S protein
To produce S-pseudotyped vectors, 293T cells were plated
into 175 cm2 flasks at a density of 8×106 cells/flask and
transfected 1 day later with 20 μg each of the vector plasmid
(VCGΔBH, HIV-CL-CG or pLEGFP-N1) and the packaging
plasmid (SgpΔ2, Hgpsyn or pHIT-60 respectively), and 10 μg
of the envelope expressing plasmid (pSwt, pSGTM or pHIT-G) as
described above. For the production of HIV-based vectors, 5 μg
of the plasmid pcTatRev was also cotransfected. Eight hours
after transfection, the conditioned media were discarded and
cells were fed with 20 ml of fresh serum-free medium (AIM-V
Invitrogen, Karlsruhe, Germany). One day later, the conditioned
media were harvested, cleared from cell debris by low speed
centrifugation and passed through a 0.45 μm filter. To determine
the vector titer, 293T cells transiently transfected with a plasmid
expressing ACE2 were plated into 24-well plates at the density
of 5×104 cells/well and infected 1 day later with serial dilutions
of the conditioned media. Two days later, GFP-positive cells
were counted under a fluorescence microscope and the vector
titers were calculated from the number of GFP-positive cells/
well.
Preparation and characterization of S exosomal vaccines
293T cells were plated in 175 cm2 tissue culture flask at a
density of 8×106 cells/flask and transfected 1 day later with
either Swt- or SGTM-expressing plasmid. Two days after
transfection, the conditioned media were harvested and the
vesicles containing in these media were pelleted by ultracen-
trifugation through 20% sucrose cushion. Western blot analysis
using an anti-S1 antibody was performed to directly compare
the incorporation of the wild-type S (Swt) and the hybrid (SGTM)
proteins into the vesicles. The pelleted vesicles were also
subjected to Western blot analysis as described above, using
1:300 diluted mouse monoclonal antibodies directed against
HSP90 or CD82 (Santa Cruz Biotechnology, Heidelberg,
Germany) respectively.
For the preparation of the exosomal vaccines, 293T cells
were plated as described above and transfected 1 day later with
80 μg of plasmid expressing the SGTM together or not with
40 μg of plasmid expressing the G protein of VSV-G. Eight
hours after transfection, cells were fed with 20 ml fresh serum-
free medium (AIM-V, Invitrogen, Karlsruhe, Germany). One
day later the conditioned media were harvested and the
exosomes were concentrated by ultracentrifugation as described
above. The pellets were resuspended into PBS and used for
Western blot analysis or kept at −80 °C for further experiments.
In order to assess the membrane-bound nature of the SGTM,
resuspended pellets obtained from the supernatant of transfected
cells by ultracentrifugation through a 20% sucrose cushion,
were incubated for 4 h at 4 °C with 30 mM of n-octyl-β-D-
glucopyranoside (OG) (Applichem, Darmstadt, Germany)
under gentle shacking in order to solubilize the cell membrane.The treated and untreated (used as control) samples were
repelleted through 20% sucrose (containing 60 mM of OG) as
described above. To assess the solubilization of the S protein,
the supernatant of the OG-treated sample was collected after
centrifugation and concentrated approximately 50-fold using
Vivaspin ultrafiltration spin column with a cut-off molecular
weight of 10, 000 (Vivaspin AG, Goetingen, Germany) as
described by the manufacturer. The presence of the S protein in
different sample preparations was assessed by Western blot
analysis. For all experiments, the conditioned media from
mock-transfected cells were concentrated by ultracentrifugation
and used as negative control.
For animal experiments, 30 μg total protein of each
exosomal vaccine was used per inoculation, as similar amount
of the S protein was observed in Western blot analysis of
different vaccine preparations. For the production of the
recombinant adenoviral vector expressing the hybrid SGTM
protein, the SGTM gene was subcloned from the pSGTM plasmid
into the pShuttle-CMVTeto2 plasmid (Kuate et al., 2004) to
generate pS-TetO2-SGTM. For the homologous recombination,
BJ-5183 bacteria cells were co-transformed by electroporation
with the linearized pS-TetO2-SGTM recombinant plasmid and
the pAd-easy1 (He et al., 1998). The resulting recombinant
plasmid was digested with PacI and transfected into 293 T-Rex
cells for viral production. Adenoviral particles were amplified
in the same cells and purified by standard cesium–chloride
gradient centrifugation as previously described (Kuate et al.,
2004). The particle concentration of the vector particles was
determined by optical density measurement as previously
described (Mittereder et al., 1996).
Immunization and challenge of animals
For the immunization five groups of 6- to 7-week-old
BL57/6 mice (Charles River Wiga GmBH, Sulzfeld, Ger-
many) were injected at the footpad, each with 30 μg (total
protein) of the exosomal vaccines. For single immunization,
animals (n=6/group) received either SGTM (group SGTM),
SGTM with VSV-G (group G+SGTM) or 5×109 particles of
recombinant adenoviral vector expressing SGTM (group Ad-
SGTM). Two weeks later blood samples were collected retro-
orbitally and animals were challenged by injection at the right
flank of 2×106 B16 melanoma cells stably expressing the
wild-type S protein (B16-S). As negative control, six naïve
mice were also challenged with B16-S cells. For the prime–
boost experiment, animals (n=5/group) either received two
injections of SGTM (group 2×SGTM) or two injection of SGTM
with VSV-G (group 2×G+SGTM) on weeks 0 and 5. One
group (SGTM+Ad-SGTM) was primed with SGTM on week 0
and boosted 5 weeks later with Ad-SGTM. One week after the
last immunization, blood samples were collected and animals
were challenged with B16-S cells as described above. The
tumor growth was monitored daily and the volume of the
tumor was determined every 3 days. The animals were
sacrificed when the tumor volume exceeded 3500 mm3. To
assess the specificity of tumor suppression, mice (n=3) were
immunized on weeks 0 and 5 with SGTM vaccines and
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the S protein.
Analysis of the immune responses
For the analysis of the binding antibodies, B16-S cells were
plated at a density of 5×105 cells/well into U-bottom 96-well
plates and incubated for 30 min at 4 °C with 1:50 dilution of
sera collected from immunized and naïve control animals. Cells
were thereafter washed twice with FACS buffer and incubated
for 20 min at room temperature with 100 μl of 1:100 diluted
FITC-labeled monoclonal antibodies against mouse immuno-
globulin (DakoCytomation GmbH, Hamburg, Germany). After
another series of 2 washes, cells were analyzed by flow
cytometry as described above and the amounts of antibodies
were expressed as mean fluorescence intensity.
For the determination of the neutralizing antibody titers, S-
pseudotyped MLV vectors were produced as described above.
For the infection, 293T cells transiently expressing the ACE2
proteins were plated into 96-well plates at a density of 2×104
cells/well. One day later, different dilutions of the sera were
incubated for 30 min at 37 °C with vector particles and the
mixtures were added in triplicate to the cells. Two days after
infection GFP-expressing cells were counted under fluores-
cence microscope and the 90% neutralization titer was
determined as the highest serum dilution inhibiting infection
by more than 90%. In order to check the specificity of the
neutralization assay, the same assay was performed using MLV
vectors containing amphotropic MLV-Env. We further com-
pared the neutralizing properties of the antisera from immunized
mice to that from a SARS-recovered patient. Two antisera were
chosen for the experiment: one with the lowest neutralizing
antibody titer (from the SGTM group) and another one with the
highest titer (from the SGTM+Ad-SGTM group). These antisera
together with that from a SARS-recovered patient were serially
diluted and incubated with S-pseudotyped MLV vectors.
Subsequently, 293T cells expressing the ACE2 receptor were
infected with these samples. Two days later the number of GFP-
positive cells was used to calculate the percentage of the vector
infectivity. A control human antiserum was used to assess the
specificity of the inhibition.
An additional neutralization assay was performed using
wild-type SARS-CoV (Frankfurt 1 strain). Antisera from each
group of immunized animals from the prime/boost regimen
were pooled and serial dilutions of these antisera were
incubated for 1 h at 37 °C with 100 TCID50/well of SARS-
CoV, and the mixtures were added in triplicates to fresh Vero
cells. As a negative control fresh media instead of virus/
antisera mixtures were added to the cells. After 3 to 5 days of
incubation, cells were monitored under the microscope for
CPE formation. The neutralizing antibody titer was given as
the inverse of the serum dilution that prevents cytopathic
effect in 66% of wells. An antiserum from a convalescent
SARS patient, differing from the patient the Frankfurt 1 SARS
strain was isolated from, was also included in the assay for a
direct comparison of its neutralizing properties with those of
the antisera from immunized mice.Statistical analysis
For the statistical analysis, the software GraphPad Prism 4
(GraphPad software Inc., San Diego, CA, USA) was used. One-
way ANOVA analysis was performed on log-transformed data
and the post test was performed if the overall P was less than
0.05. For the post test, the Bonferroni's multiple comparison
test was performed. To compare the neutralizing antibody titers
between groups, the non-parametric Mann–Whitney test was
performed.
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